Inflammatory breast cancer (IBC) and patterns of recurrence: Understanding the biology of a unique disease

Cancer

Volumn 110, Issue 7, 2007, Pages 1436-1444

  Cristofanilli, Massimo ^a   Valero, Vicente ^a   Buzdar, Aman U ^a   Kau, Shu Wan ^a   Broglio, Kristine R ^a   Gonzalez Angulo, Ana Maria ^a   Sneige, Nour ^a   Islam, Rabiul ^a   Ueno, Naoto T ^a   Buchholz, Thomas A ^a   Singletary, Sonja E ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Inflammatory breast cancer (IBC); Locally advanced breast cancer (LABC); Neoadjuvant therapy; Prognosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER RECURRENCE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTITIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SOFT TISSUE METASTASIS;

ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFLAMMATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SOFT TISSUE NEOPLASMS;

EID: 34648822744     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22927     Document Type: Article

References (42)

1. Lee B, Tannenbaum N. Inflammatory carcinoma of the breast: a report of twenty-eight cases from the breast clinic of Memorial Hospital. Surg Gynecol Obstet. 1924;39:580-595.
2. Haagensen C. Diseases of the breast, 2nd ed. Philadelphia: Saunders; 1971:576-584.
3. Chang S, Parker SL, Pham T, Buzdar AU, Hursting SD. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer. 1998;82:2366-2372.
4. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst. 2005;97:966-975.
5. Anderson WF, Chu KC, Chang S. Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinoma: distinct clinicopathologic entities? J Clin Oncol. 2003;21:2254-2259.
6. Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist. 2003;8:141-148.
7. Panades M, Olivotto I, Speers CH, et al. Evolving treatment strategies for inflammatory breast cancer: a population-based survival analysis. J Clin Oncol. 2005;23:1941-1950.
8. Low JA, Berman AW, Steinberg SM, Danforth DN, Lippman ME, Swain SM. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22:4067-4074.
9. Van Laere S, Van der Auwera I, Van den Eynden GG, et al. Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. Breast Cancer Res Treat. 2005;93:237-246.
10. Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995;4:715-734.
11. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 1997;40:321-329.
12. Cristofanilli M, Buzdar AU, Sneige N, et al. Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. Cancer. 2001;92:1775-1782.
13. Cristofanilli M, Gonzalez-Angulo AM, Buzdar AU, Kau SW, Frye DK, Hortobagyi GN. Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2004;4:415-419.
14. Ueno NT, Konoplev S, Buchholz TA, et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy. Bone Marrow Transplant. 2006;37:929-935.
15. Hortobagyi GN, Buzdar AU, Strom EA, et al. Primary chemotherapy for early and advanced breast cancer. Cancer Lett. 1995;90:103-109.
16. Kuerer HM. Newman LA. Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999;17:460-469.
17. Comment in: J Clin Oncol. 1999;17:441-444.
18. Thomas E, Holmes FA, Smith TL, et al. The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 2004;22:2294-2302.
19. th ed. New York: Springer; 2002.
20. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695-706.
21. Pepe M, Mori M. Kaplan-Meier marginal or conditional probability curves in summarizing competing risks failure time data? Stat Med. 1993;12:737-751.
22. Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer. 2006;106:1000-1006.
23. Cristofanilli M, Singletary ES, Hortobagyi GN. Inflammatory breast carcinoma: the sphinx of breast cancer research. J Clin Oncol. 2004;22:381-383; author reply, 383.
24. Comment on: J Clin Oncol. 2003;21:2254-2259.
25. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793-802.
26. Comment in: N Engl J Med. 2005;353:2191; author reply 2191.
27. Van der Auwera I, Van den Eynden GG, Colpaert CG, et al. Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res. 2005;11:7637-7642.
28. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res. 2002;62:560-566.
29. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res. 2001;61:445-451.
30. Tomlinson JS, Alpaugh ML, Barsky SH. An intact overexpressed E-cadherin/alpha, beta-catenin axis characterizes the lymphovascular emboli of inflammatory breast carcinoma. Cancer Res. 2001;61:5231-5241.
31. van Golen KL, Wu ZF, Qiao XT, Bao LW, Merajver SD. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res. 2000;60:5832-5838.
32. Kleer CG, Zhang Q, Pan Q, et al. WISP3 is a novel tumor suppressor gene of inflammatory breast cancer. Oncogene. 2002;21:3172-3180.
33. Muller A, Homey B, Soto H, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410:50-56.
34. Smith MC, Luker KE, Garbow JR, et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res. 2004;64:8604-8612.
35. Salvucci O, Bouchard A, Baccarelli A, et al. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study. Breast Cancer Res Treat. 2006;97:275-283.
36. Cabioglu N, Gong Y, Islam R, et al. Expression of growth factor and chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann Oncol. 2007;18:1021-1029.
37. Roberts N, Kloos B, Cassella M, et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006;66:2650-2657.
38. Comment in: Cancer Res. 2007;67:5055; author reply 5056.
39. th Meeting of the American Association of Cancer Research, Los Angeles, California, April 14-18, 2007. Abstract 5743. Available at: http://www.aacr.org/.
40. Singletary SE, Allred C, Ashley P, et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 2003;83:803-819.
41. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-d-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med. 2001;28:351-358.
42. Baslaim MM, Bakheet SM, Bakheet R, Ezzat A, El-Foudeh M, Tulbah A. 18-Fluorodeosyglucose-positron emission tomography in inflammatory breast cancer. World J Surg. 2003;10:1099-1104.